-
01:12:45 PM

LTRN Stock News

09/25/23 8:30 AM
Nasdaq : LTRN
clinical triallow float
Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors
Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platform, RADR ®, with multiple clinical stage drug programs, today announced the dosing of the first patient in the Phase 1 clinical trial evaluating Lantern’ s investigational new drug LP-184 in...
RHEA-AI
neutral
09/18/23 9:00 AM
Nasdaq : LTRN
clinical triallow float
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas
Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platform, RADR ®, with multiple clinical stage drug programs, today announced that the United States Food and Drug Administration has cleared the investigational new drug application for...
RHEA-AI
neutral
08/31/23 8:00 AM
Nasdaq : LTRN
conferenceslow float
Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting
Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platform, RADR ®, with multiple clinical stage drug programs, today announced that it will present positive data highlighting the anti-tumor potency of its drug candidate LP-284 for...
RHEA-AI
positive
08/28/23 8:00 AM
Nasdaq : LTRN
clinical trialAIlow float
Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors
Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platform, RADR ®, with multiple clinical stage drug programs, today announced a substantial increase in the power and capabilities of RADR ® focused on improving the drug development process...
RHEA-AI
neutral
08/14/23 8:30 AM
Nasdaq : LTRN
low float
Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT
Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning platform with multiple clinical-stage drug programs, received a notice of allowance from the United States Patent and Trademark Office covering a method of treatment for Atypical...
RHEA-AI
neutral
08/02/23 8:00 AM
Nasdaq : LTRN
conferencesearningslow float
Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET
Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning platform with multiple clinical stage drug programs, today announced that it will host its second quarter 2023 operating and financial results webcast on Wednesday, August 9, 4:30 p.m....
RHEA-AI
positive
06/26/23 8:30 AM
Nasdaq : LTRN
AIlow float
Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas
Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning platform with multiple clinical stage drug programs, today announced the company has published new findings in Oncotarget demonstrating drug candidate LP-284’ s in vitro and in vivo...
RHEA-AI
neutral
06/08/23 9:00 AM
Nasdaq : LTRN
AIlow float
Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University
Lantern Pharma Inc., a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it will be leveraging its AI platform, RADR ®, in a research collaboration with Bielefeld University to...
RHEA-AI
positive